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ABSTRACT 
HIV-1 replication is efficiently controlled by the regulator protein Tat (101 amino acids) 
and codified by two exons, although the first exon (1–72 amino acids) is sufficient for 
this process. Tat can be released to the extracellular medium, acting as a soluble pro-
apoptotic factor in neighboring cells. However, HIV-1-infected CD4 T lymphocytes 
show a higher resistance to apoptosis. We observed that the intracellular expression of 
Tat delayed FasL-mediated apoptosis in both peripheral blood lymphocytes and Jurkat 
cells, as it is an essential pathway to control T cell homeostasis during immune 
activation. Jurkat T at cells showed impairment in the activation of caspase-8,deficient 
release of mitochondrial cytochrome c, and delayed activation of both caspase-9 and -3. 
This protection was due to a profound deregulation of proteins that stabilized the 
mitochondrial membrane integrity, such as heat shock proteins, prohibitin, or 
nucleophosmin, as well as to the up-regulation of NF-Bdependent anti-apoptotic proteins, 
such as BCL2, c-FLIPS, XIAP, and C-IAP2. These effects were observed in Jurkat 
expressing full-length Tat (Jurkat-Tat101) but not in Jurkat expressing the first exon of 
Tat (Jurkat-Tat72), proving that the second exon, and particularly the NF-B-related motif 
ESKKKVE, was necessary for Tat-mediated protection against FasL apoptosis. 
Accordingly, the protection exerted by Tat was independent of its function as a regulator 
of both viral transcription and elongation. Moreover, these data proved that HIV-1 could 
have developed strategies to delay FasL-mediated apoptosis in infected CD4 T 
lymphocytes through the expression of Tat, thus favoring the persistent replication of 
HIV-1 in infected T cells. 
Background: HIV-infected T cells are quite resistant to apoptosis. 
Results: Intracellular expression of HIV-1 Tat in T cells stabilized the mitochondrial 
membrane and reduced caspase activation mainly through NF-B activation. 
Conclusion: Intracellular Tat induced resistance to FasL-mediated apoptosis in T cells 
mainly through the second exon. Significance: Tat-mediated protection against apoptosis 
may be a mechanism for HIV-1 persistence. 
 
INTRODUCTION 
The human immunodeficiency virus type 1 (HIV-1) infection is characterized by a 
continuous viral replication in CD4 T lymphocytes and macrophages (1), leading 
ultimately to the development of the acquired immunodeficiency syndrome (AIDS). This 
is caused by a progressive depletion of CD4 T lymphocytes through different 
mechanisms such as apoptosis, cellular syncytia, plasma membrane disruption by viral 
budding, or cytotoxicity by soluble viral proteins as Tat, Nef, and gp120 (2–4). Vpr may 
also have a cytotoxic effect on bystander or infected CD4 T cells by increasing the 
mitochondrial membrane permeabilization (5–8), although it has also been described as 
an anti-apoptotic factor (9, 10). The programmed cell death or apoptosis of CD4 T cells 
during HIV-1 infection is a complex process that affects differently both infected and 
uninfected cells. Apoptosis occurs mainly in bystander noninfected cells, whereas 
productively HIV-1-infected cells have evolved strategies to prevent or delay apoptosis 
in the context of immune activation (11–14). 
HIV-1 regulator Tat induces apoptosis of bystander cells when is released to the 
extracellular medium as a soluble form (15). However, when Tat is expressed 
intracellularly, it produces the efficient elongation of the viral transcripts through the 
recruitment of the RNA polymerase II complex. Tat binds to a stem-loop RNA termed 
Tat-response element, located at the 5 end of the nascent viral transcripts (16), and 
activates the recruitment of cellular elongation factors such as P-TEFb, increasing the 
processivity of RNA polymerase II (17). Tat is a 101-residue-long protein codified by 
two exons as follows: the first exon codifies amino acids 1–72, forming the 
transcriptionally active protein Tat72; and the second exon codifies amino acids 73–101 
and overlaps with the env gene (18, 19). The Tat first exon (1–72 amino acids) contains 
the minimal functional domain to generate a protein competent in HIV-1 replication 
through a Tat-response element-dependent activation of the transcription, and the second 
exon (73–101 amino acids) has been described as dispensable for Tat activity (20). 
However, expression of the Tat second exon is conserved in all lentivirus, suggesting 
biological importance. In fact, the second exon is essential for Tat-mediated cell genome 
deregulation, thereby indicating that it may control the transcription of nonviral genes 
(Tat-response element-independent activation) (21–23), probably through binding to 
canonical enhancer sequences of cellular transcription factors such as NF-B or Sp1 (24–
26). This would indirectly affect the expression of several genes related to cellular 
functions such as T cell activation or apoptosis (15, 23, 27, 28). Moreover, the important 
contribution of Tat second exon to HIV-1 in vivo replication was demonstrated by the 
accidental infection of three laboratory workers with the HIV-1 HXB2 isolate, which 
shows a premature stop codon at the residue 89 (29, 30). In one of the infected patients, 
the HXB2 virus with first exon Tat reverted to second exon Tat (30), changing the mild 
course of the infection to a steep decline in CD4 T cell count and a rapid progression to 
AIDS within 1 year (29). This unfortunate situation provided conclusive evidence for the 
biological requirement of the Tat second exon for HIV-1 replication and pathogenesis in 
vivo. 
The role of Tat in apoptosis of bystander and infected cells is controversial because, 
although soluble Tat has been described as an inductor of apoptosis (15, 31, 32), it has 
also been proved to be a protector against apoptosis when it is expressed inside the host 
cell (28, 33). Our group demonstrated previously that intracellular Tat profoundly 
deregulates cellular gene expression, modifying the expression of genes involved in 
apoptosis (23). This deregulation was mainly due to the presence of the second exon, 
proving that although the first exon is sufficient for activating viral replication, full-
length Tat should exert further control on HIV-1 pathogenesis by protecting the host cells 
against apoptosis. Apoptosis is essential to control T cell homeostasis, especially during 
the contraction of the immune response (34). As the antigen wanes, the number of T cells 
is appropriately reduced through the induction of apoptosis by Fas (CD95 or Apo-1), a 
member of the tumor necrosis factor receptor superfamily (35). Engagement of Fas 
receptor/CD95 with Fas ligand (FasL)/CD178 or Fas-activating antibodies (anti-CD95) 
recruits procaspase-8 to death-inducing signaling complex (DISC)1 through the FADD 
adapter protein. Within DISC, procaspase-8 is activated by dimerization and 
autocleavage (36–38). After that, Fas may activate apoptosis through two different 
pathways that distinguish type I and type II cells. Most cell types are classified as type I, 
where caspase-8 directly activates caspase-3, the main effector of the morphological and 
biochemical changes characteristic of apoptosis (36, 37). In type II cells, Fas receptors 
are excluded from lipid rafts and assemble DISC inefficiently upon activation of death 
                                                          
 
receptors (39). Consequently, only a small fraction of procaspase-8 is activated; 
therefore, they require a subsequent amplification step through the mitochondrial cell 
death pathway. The mitochondria are highly involved in the induction of apoptosis in 
mammalian cells as they release to the cytosol many important factors that induce 
caspase activation and chromosome fragmentation after the permeabilization of the 
mitochondrial outer membrane (40, 41). This mechanism is controlled by proand anti-
apoptotic members of the BCL2 family such as the “BH3-domain only” protein Bid (42). 
Caspase-8-mediated cleavage of Bid initiates the mitochondrial cell death pathway (43–
45) as truncated Bid (tBid) translocates to the mitochondrial membrane and triggers the 
release of cytochrome c to the cytosol (46). Cytochrome c participates then in the 
assembly of the apoptosome, a multiprotein complex required for caspase-9 activation 
that subsequently activates caspase-3 (47, 48). 
Apoptosis is tightly controlled by many cellular proteins at different levels, and the final 
cell death occurs by imbalance between pro- and anti-apoptotic factors. One central 
regulator of cell survival and apoptosis is the transcription factor NF-B that regulates the 
expression of anti-apoptotic genes such as BCL2, c-IAP, XIAP, as well as the cellular 
FLICE-inhibitory protein (c-FLIP) (49). Upstream in the apoptotic pathway, c-FLIP 
interferes with FasL-mediated activation through the binding to FADD and/or caspase-
8/10 in a ligand-dependent manner, preventing DISC formation (50). There are three 
functional c-FLIP splice variants as follows: short form (c-FLIPS, 26 kDa) (51); 
intermediate or Raji form (c-FLIPR, 43 kDa) (52); and long form (c-FLIPL, 55 kDa) (53). 
c-FLIPS is exclusively a caspase-8 inhibitor, whereas c-FLIPL has dual function as 
caspase-8 inhibitor or activator, depending on the different ratios of c-FLIPL/caspase-8 
(54). The mechanisms by which intracellular Tat interferes with apoptosis are not well 
known, although it has been described that Tat may enhance the expression of anti-
apoptotic factors such as c-FLIP (33) or BCL2 (55, 56). The role of the second exon in 
the ability of Tat to protect against apoptosis is completely unknown. 
It was determined that the intracellular expression of fulllength Tat was able to delay 
Fas-mediated apoptosis in both PBLs and Jurkat and that this effect was due to the 
presence of the second exon. The mechanism of protection was based on the following: 
first on the deregulation of several NF-B-dependent proteins, including the 
overexpression of BCL2 and c-FLIPS, and second on the preservation of the 
mitochondrial outer membrane integrity by several anti-apoptotic factors, delaying the 
release of cytochrome c and subsequent activation of caspase-9 and caspase-3. Getting 
further insight on this mechanism of protection against apoptosis in CD4 T cells 
mediated by intracellular full-length Tat would provide a better understanding of the role 
of Tat in the ability of HIV-1 to create a persistent infection in the host. 
 
EXPERIMENTAL PROCEDURES 
Cells—PBLs were isolated from the blood of healthy donors by centrifugation through a 
Ficoll-Hypaque gradient (GE Healthcare). Jurkat E6-1 cells were obtained from the 
AIDS Reagent Program, National Institutes of Health (57). JurkatTat72 and Jurkat-
Tat101 stably express, respectively, the HIV-1 Tat first exon (1–72 amino acids) or full-
length Tat (1–101 amino acids) by using a Tet-Off system Clontech. Jurkat TetOff cells 
transfected with empty vector pTRE2hyg were used as negative control. Jurkat-Tat72 
and Jurkat-Tat101 are not clones but are mixed populations in which more than 50% of 
the cells express high amounts of intracellular Tat101 or Tat72 protein. It was determined 
that the expression of Tat in JurkatTat101 and Jurkat-Tat72 was very similar to a real 
infection performed in MT-2 cells infected with the NL4.3WT strain (23). Both PBLs 
and Jurkat were cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal calf 
serum (FCS), 2 mM L-glutamine, 100 g/ml streptomycin, 100 units/ml penicillin 
(BioWhittaker, Walkersville, MD). In Jurkat-Tat cells, the culture medium was 
supplemented with 300 g/ml geneticin (Sigma) and 300 mg/ml hygromycin B (Clontech). 
Reagents and Antibodies—A monoclonal antibody against HIV-1 Tat (amino acids 2–9) 
was obtained from Advanced Biotechnologies Inc. (Columbia, MD). A monoclonal 
antibody against human Fas receptor (MBL International, Woburn, MA; clone SY-001) 
was used at 50 or 500 ng/ml during 4 or 18 h at 37 °C for inducing cell death in Jurkat or 
PBLs, respectively, and for quantifying the amount of Fas receptor on the cell surface by 
flow cytometry. A polyclonal antibody against procaspase 3 (p32) and active subunits 
p17 and p20 (clone H-277) was obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA). A monoclonal antibody against procaspase 8 (p55) (clone 90A992) was also 
obtained from Santa Cruz Biotechnology. A monoclonal antibody against procaspase 9 
(p46) and active p35/p37 (clone 5B4) was obtained from Abcam (Cambridge, UK). 
Antibodies against BCL2 (clone C-2), Bid (clone 5C9), poly(ADP-ribose) polymerase 
(PARP-1) (clone 194C1439), c-FlipS/L (clone G-11), and p65/RelA (clone C-20) were 
obtained from Santa Cruz Biotechnology. The monoclonal antibody against cytochrome 
c was obtained from Calbiochem. A monoclonal antibody against -actin (clone AC-15) 
was obtained from Sigma. Propidium iodide (PI) and 4,6-diamidino-2-phenylindole 
(DAPI) were also obtained from Sigma. MitoTracker Red CMxRos mitochondrial probe 
was obtained from Lonza. Secondary antibodies conjugated to Alexa 488 and Alexa 546 
were purchased from Molecular Probes (Eugene, OR). Secondary antibodies conjugated 
with horseradish peroxidase (HRP) were purchased from GE Healthcare. Secondary 
IgG/IgM antibody fluorescein-conjugated (FITC) used in flow cytometry assays was 
purchased from Jackson ImmunoResearch (West Grove, PA). 
Transient Transfection and Vectors—Resting PBLs and Jurkat cells were transiently 
transfected with an Easyjet Plus Electroporator (EquiBio, Middlesex, UK). In brief, 20  
106 PBLs or 107 Jurkat were collected in 350 l of RPMI 1640 medium without 
supplement and mixed with 1 g/106 cells of plasmid DNA. Cells were transfected in a 
cuvette with a 4-mm electrode gap (EquiBio) at 340 V for PBLs and 280 V for Jurkat, 
1500 microfarads, and maximum resistance. 
pCMV-Tat72tagorpCMV-Tat101tagexpressionvectorswere obtained by cloning Tat72 
and Tat101, obtained from the pCMVTat101 vector (58), in pCMV tag (Stratagene, 
Agilent Technologies,Madrid,Spain),inNotI/BamHI.pNL4.3-TatM1I,whichcontains a 
point mutation in the start codon of the tat gene, was obtained from pNL4.3 wild-type 
(WT) vector (kindly provided by Dr. M. A. Martin (59)) by site-directed mutagenesis 
with the QuikChange site-directed mutagenesis kit (Stratagene), using the following 
oligonucleotide: 5-TCGACAGAGGAGAGCAAGAAATTGAGCCAGTAGAT-3, which 
introduced a point mutation (underlined) in the start codon, changing a methionine by an 
isoleucine (supplemental Fig. 1). The presence of the selected mutation was confirmed 
by automatic sequencing. pNL4.3-TatM1I vector was co-transfected along with 
pCMVTat72 or pCMV-Tat101 in a ratio of 2:1. pEYFP-C1 vector (Clontech) was co-
transfected as control of transfection efficiency and measured by flow cytometry. 
Quantitative PCR—Total RNA was isolated with RNeasy mini kit (Qiagen Iberia, 
Madrid, Spain), and cDNA was synthesized by using the GoScript Reverse Transcription 
System (Promega), according to manufacturer’s instructions. HIV-1 transcription was 
determined by quantitative PCR analysis of all viral mRNAs using the following primers 
directed against env/ nef genes: P3 (5-TTGCTCAATGCCACAGCCAT-3) and P4 (5-
TTTGACCACTTGCCACCCAT-3) (60). The expression of -ACTIN was used as 
housekeeping gene to calculate the relative expression of env/nef genes. Primers for 
amplifying the human -ACTIN gene were -actin sense (5-
AGGCCCAGAGCAAGAGAGGCA-3) and -actin antisense (5-
CGCAGCTCATTGTAGAAGGTGTGGT-3). SYBR Green PCR master mix (Applied 
Biosystems) was used according to manufacturer’s instructions. 
Analysis of Apoptosis—Cells were stained with 1.5 M PI or annexin-V conjugated with 
fluorescein isothiocyanate (FITC) (Immunostep, Salamanca, Spain), and fluorescence 
was measured by a FACSCalibur flow cytometer (Clontech). Data were analyzed by 
CellQuest software. Cell viability was also determined by using the CellTiter-Glo 
luminescent cell viability assay (Promega), following the manufacturer’s instructions. 
Briefly, 1  105 cells were harvested by centrifugation, washed twice with 1 PBS, and 
resuspended in lysis buffer. After incubation for 10 min at room temperature to stabilize 
the luminescent signal, cell lysates were deposited in an opaque-walled multiwell plate 
and analyzed in an Orion microplate luminometer with Simplicity software (Berthold 
Detection Systems, Oak Ridge, TN). 
Immunoblotting Assays—Nuclear and cytosolic protein fractions were obtained as 
described previously (61). Protein extracts were fractionated by SDS-PAGE and 
transferred onto a Hybond-ECL nitrocellulose paper (GE Healthcare). After blocking and 
incubation with primary and secondary antibodies, proteins were detected by 
chemiluminescence with SuperSignal West Pico/Femto chemiluminescent substrate 
(Pierce). Densitometry was performed in a Gel Doc 2000 System (BioRad) by using 
Quantity One software. Gel bands were quantified, and background noise was subtracted 
from the images. The relative ratio of the optical density units corresponding to each 
sample was calculated regarding the internal control (-actin) per each lane. 
Immunofluorescence Assays—Living cells treated or not with anti-CD95 for 4 h were 
stained with MitoTracker and then adhered onto PolyPrep slides (Sigma) and fixed with 
2% paraformaldehyde in 1 PBS. Immunofluorescence assays were then performed as 
described previously (23). Images were obtained with a Leica DMI 4000B Inverted 
Microscope (Leica Microsistemas, Barcelona, Spain). 
Measurement of Caspase Activity—Activity of caspase-3/-7, -8, and -9 was measured 
with CaspaseGlo3/7, CaspaseGlo8, and CaspaseGlo9 systems (Promega Biotech Iberica, 
Madrid, Spain), respectively. The luminescent signal (relative light units (RLUs)), which 
was directly proportional to caspase activation, was measured in an Orion microplate 
luminometer with Simplicity software (Berthold Detection Systems), and data were 
normalized according to the protein concentration in each sample. 
Mitochondrial Cytochrome c Depletion—The release of cytochrome c from the 
mitochondria intermembrane space to the cytosol was measured by using InnoCyte flow 
cytometric cytochrome c release kit (Calbiochem). Briefly, 5  106 cells treated or not with 
FasL were permeabilized and then fixed with paraformaldehyde. After staining with a 
primary monoclonal antibody against cytochrome c and a secondary antibody conjugated 
with FITC, the measurement of cytochrome c release was performed by flow cytometry. 
Mitochondrial Membrane Potential Gradient (m)—m was measured by flow cytometry 
using MitoProbe JC-1 assay kit (Molecular Probes), accordingly to manufacturer’s 
instructions. Briefly, 2  106 cells/ml were incubated in JC-1 staining solution, and both 
green and red fluorescence were measured in FL1 and FL2 channels, respectively, by 
flow cytometry. The mitochondrial depolarization was calculated by measuring the 
decrease in the red/green fluorescence intensity ratio. 
NF-BActivationAssays—The ability of NF-B to bind DNA was measured in nuclear 
protein extracts by DNA affinity immunoblotting assay, as described previously (23, 62). 
The quantity of NF-B bound to DNA was detected by immunoblotting with a polyclonal 
antibody against p65/RelA (Santa Cruz Biotechnology). As internal control, an input of 
nuclear protein for each sample was analyzed by using an antibody against -actin 
(Sigma). 
NF-B transactivation activity was measured by transient transfection with p3B-LUC 
vector, which contains a luciferase gene under the control of three -B consensus sites 
from the immunoglobulin -chain promoter, as described before (23, 58). After incubation 
for 18 h, cell were treated or not with 50 ng/ml anti-CD95 for 4 h, and then the luciferase 
activity was measured by using luciferase assay system (Promega) in a Sirius 
luminometer (Berthold Detection Systems), according to the manufacturer’s instructions. 
The RLUs were normalized with protein concentration in each sample and with the 
percentage of efficiently transfected cells by using pEYFP-C1 vector as transfection 
internal control. 
Tat101 Site-directed Mutagenesis—Site-specific mutagenesis of the 85ESKKKVE91 
sequence necessary for Tat-mediated NF-B activity, located in Tat second exon, was 
performed in the pTRE2hyg-Tat101 vector (28) by using QuikChange sitedirected 
mutagenesis kit (Stratagene, Agilent Technologies), according to manufacturer’s 
instructions. The following oligonucleotide was used to introduce selected mutations 
(underlined) in the 85ESKKKVE91 motif to generate the motif 85ESRVNVV91: 5-
AGACGGAATCGAGGGTGAACGTGGTGAGAGAGACAGAGACAGAT-3. The 
presence of the selected mutations was confirmed by automatic sequencing. 
Proteome Profiling—Two hundred micrograms of protein extracts were subjected to 
reduction and alkylation and then digested with trypsin (Promega) in 50 mM ammonium 
bicarbonate, pH 8.8. The resulting tryptic peptides were loaded into the liquid 
chromatography/tandem mass spectrometry (LCMS/MS) system and analyzed by using a 
C-18 reversed phase nano-column (75-mm inner diameter  25 cm, 3-mm particle size, 
Acclaim PepMap 100 C18, Thermo-Fisher) in a continuous acetonitrile gradient 
consisting of 0–30% B in 145 min, 30–43% A in 5 min, and 43–90% B in 1 min (A  
0.5% formic acid; B  95% acetonitrile, 0.5% formic acid). A flow rate of 300 nl/min was 
used to elute peptides from the reverse phase nano-column to an emitter nanospray 
needle for real time ionization and peptide fragmentation on an orbital ion trap mass 
spectrometer (LTQ Orbitrap XL, Thermo Fisher Scientific) (63). An enhanced resolution 
spectrum (resolution  60,000) followed by the MS/MS spectra from the five most intense 
parent ions were analyzed during the chromatographic run (180 min). Dynamic exclusion 
was set at 0.5 min. For peptide identification, all spectra were analyzed with Proteome 
Discoverer (version 1.2, Thermo Fisher Scientific), using both Sequest (Thermo Fisher 
Scientific; version 1.0.43.2) (64) and Mascot search engines. For database searching, a 
Uniprot database was interrogated selecting the following parameters: trypsin digestion 
with two maximum missed cleavage sites, precursor mass tolerance of 20 ppm, fragment 
mass tolerance of 1200 millimass units, carbamidomethylcysteine as fixed modification, 
and methionine oxidation, asparagine deamidation, and serine and threonine 
phosphorylation as dynamic modifications. For peptide and protein identification 
validation, results were loaded into Scaffold 3.0 software (Proteome Software Inc., 
Portland, OR), adding X!Tandem as an dditional search engine. Sequest search engine 
facilitates the “XCorr score” (values above 2.0), which measures how close the spectrum 
detected in the sample fits to the ideal spectrum. Differential expression in samples was 
determined using the quantity values of normalized spectra for each peptide, as 
determined by Scaffold software in a triplicate experiment. Peptide identifications were 
accepted if they could be established at greater than 95.0% probability as specified by the 
Peptide Prophet algorithm (65). Only those proteins involved in apoptotic pathways, cell 
survival, and mitochondrial function were selected for further analysis. 
Antibody-based Apoptosis Microarray—RayBio human apoptosis antibody array kit 
(RayBiotech Inc., Norcross, GA) detects the relative level of 43 apoptosis-related 
proteins in cell lysates by using an array of antibodies spotted on a glass chip. Procedure 
was performed according to manufacturer’s instructions. All microarrays were scanned 
under the same conditions in a ScanArray Express HT microarray scanner (PerkinElmer 
Life Sciences) using Alexa 555-specific filters. Images were quantified by QuantArray 
analysis software and a fixed circle segmentation algorithm. Data were filtered to discard 
those data points that were not considered positive with respect to the local background 
and the local negative controls. A second filtering round was done by removing from 
further analyses those proteins with less than three passing data points. Data were 
normalized against the positive controls of each array and then were mean-aggregated to 
result in a single value for each analyzed protein. Normalized data points where then 
logarithmically transformed for data compression and a better visualization of the results. 
Finally, logarithmic ratios (log2 ratios) against the reference data obtained from control 
cells were generated. Only proteins that were deregulated in Jurkat-Tat101 and Jurkat-
Tat72 versus Jurkat Tet-Off cells were represented. 
Apoptosis-related Protein Networks—All proteins related to apoptosis that were 
deregulated were subjected to analysis with STRING 9.0 (66). Deregulated proteins were 
integrated in interconnected networks built by inputting the list of protein symbols, 
selecting Homosapiens as organism and medium confidence, which does not consider 
interactions with combined scored under 0.4. 
StatisticalAnalysis—Statistical analysis was performed using GraphPad Prism 5.0 
(GraphPad Software Inc., San Diego, CA). Corporations between control and FasL 
treatment groups were made using two-way analysis of variance (ANOVA) with 
Bonferroni pos-test analysis to describe the statistical differences among groups. p values 
0.05 were considered statistically significant in all comparisons and were represented as 
*, **, or *** for p  0.05, p  0.01, or p  0.001, respectively. 
 
RESULTS 
Apoptosis Induced by FasL Is Delayed in PBLs Transiently Transfected with Tat101 
Alone or in the Context of HIV-1 Genome—PBLs from healthy donors were transfected 
with pCMV-Tat101 or pCMV-Tat72 expression vectors. Transfection with pcDNA3 was 
used as negative control, and pEYFP-C1 was co-transfected in all cases as a control of 
transfection efficiency. Viability after transfection was 40–45% (data not shown), and 
transfection efficiency was 20–25%, depending on the batch of PBLs. Transfected PBLs 
were cultured for 3 days and then treated with FasL for 18 h. Viability was measured by 
chemiluminescence. Media from three different independent experiments are represented 
in Fig. 1A. It was observed that the intracellular expression of Tat101 in PBLs was able 
to exert 2.0-fold more protection against FasL-mediated apoptosis than control cells (p  
0.01), whereas Tat72 exerted lower protection. The efficient expression of Tat72 and 
Tat101 was assessed in EYFP cells by immunofluorescence (Fig. 1B), using DAPI to 
stain the nucleus, where most Tat was localized. To evaluate whether the resistance to 
apoptosis occurred mainly on CD4+ T cells, the transfected PBLs challenged with FasL 
for 18 h were stained with an antibody against CD4 conjugated with phycoerythrin (PE) 
and then analyzed by flow cytometry. PI- cells were gated and EYFP+/CD4+ cells were 
quantified within this group. It was determined that Tat101 alone was able to induce 2-
fold more protection against FasL-mediated apoptosis than Tat72 or empty vector 
pcDNA3 in CD4 T cells (Fig. 1C). 
The role of Tat in the protection against FasL apoptosis was also evaluated in the context 
of viral replication. PBLs were transfected with the Tat-defective viral genome 
pNL4.3TatM1I (described in supplemental Fig. 1) along with pCMVTat101 or pCMV-
Tat72 expression vectors. Viability was measured by chemiluminescence, and it was 
determined that Tat101 produced 1.7-fold more protection against apoptosis induced by 
FasL than control cells (p  0.01), whereas Tat72 exerted lower protection (Fig. 2A). HIV-
1 replication was assessed by quantitative RT-PCR (Fig. 2B). It was also evaluated 
whether the cells showing higher protection against apoptosis were CD4 T cells. PBLs 
were then transfected with pCMVTat101 or pCMV-Tat72 expression vectors alone or 
along with pNL4.3-TatM1I, using pEYFP-C1 as control of transfection efficiency. As 
Tat is not known to be packaged inside the virions (67) and the viral genome NL4.3-
TatM1I of the new generated virions did not produce Tat, only transfected cells would 
express the viral proteins encoded in the defective viral genome. After 3 days in culture, 
cells were challenged with FasL for 18 h and then stained with anti-CD4. As described 
above, the quantification of apoptosis was performed in EYFP/CD4 cells after selecting 
living PI cells (Fig. 2C). The results obtained were quite similar to those when only 
Tat101 or Tat72 was expressed, proving that Tat was a significant viral protein in the 
induction of resistance to FasL-mediated apoptosis in infected CD4 T cells, despite the 
presence of other viral proteins such as Nef, Vpr, or gp120. 
FasL-mediated Apoptosis Is Delayed in Jurkat Cells with Transient or Stable Expression 
of Tat101 or Tat72—As a model of CD4 T cells was necessary to dissect the mechanism 
of action of Tat to exert protection against FasL-mediated apoptosis, the potential use of 
Jurkat cells for this purpose was evaluated. Jurkat E6-1 cells were transiently transfected 
with the Tatdefective viral genome pNL4.3-TatM1I along with pCMVTat101 or pCMV-
Tat72 expression vectors. Transfection with pcDNA3 was used as negative control, and 
pEYFP-C1 was cotransfected as control of transfection efficiency, which was 20–25% in 
all cases. HIV-1 replication was assessed by quantitative RT-PCR. Efficient expression 
of Tat72 and Tat101 was assessed by immunofluorescence (data not shown). Transfected 
Jurkat cells were cultured for 3 days and then treated with FasL for 4 h. Cell viability was 
measured by luminometric assay, and the media of three different independent 
experiments were represented as a ratio of the apoptosis induced in FasL-treated PBLs 
regarding untreated cells (Fig. 3A, 1st bar diagram). It was observed that the intracellular 
expression of Tat101 in Jurkat cells produced 1.8-fold more protection against FasL-
mediated apoptosis than control cells, whereas Tat72 exerted lower protection (p  0.05). 
To dissect the mechanism underlying intracellular Tat-mediated protection against 
apoptosis by FasL in T cells, the use of Jurkat-Tat101 and Jurkat-Tat72 stable cell lines 
was analyzed. Jurkat-Tat101 and Jurkat-Tat72 were treated with FasL at different times, 
and early apoptosis was measured by annexin-VFITC staining (Fig. 3B). Flow cytometry 
analysis showed that the percentage of pro-apoptotic cells was 1.8-fold lower on average 
in Jurkat Tat101 than in control cells, whereas this percentage in Jurkat Tat72 was 1.2-
fold lower on average than control. Measurement of apoptosis by PI staining in Jurkat-
Tat72 and Jurkat-Tat101 treated with FasL for 4 h showed that Tat101 delayed 4.6-fold 
the induction apoptosis, whereas Tat72 delayed apoptosis 1.7-fold (Fig. 3C). The 
expression of Fas receptors/CD95 on the cell surface was increased by 20% in Tat101, 
but Tat 72 did not produce significant changes (Fig. 3D). 
FasL-mediated Activation of Caspase-8 and -3 Is Decreased in Jurkat-Tat101 Cells—
Cleavage of procaspase-3 was analyzed by immunoblotting in protein extracts obtained 
from Jurkat-Tat101, Jurkat-Tat72, and control cells treated with FasL for 4 or 18 h. As 
shown Fig. 4A, the active subunits p17 and p11 were rapidly generated in Jurkat-Tat72 
and control cells after treatment with FasL for 4 h. After 18 h of treatment, the cleavage 
of caspase-3 was also initiated in Jurkat-Tat101, although 2-fold more of high quantity 
unprocessed precursor p32 could also be observed in these cells. 
To further evaluate the activation of caspase-3 in Jurkat-Tat cells treated with FasL, the 
cleavage of the caspase-3 substrate PARP-1 was analyzed by immunoblotting. PARP-1 
cleaved from p89 was abundantly detected in the cytoplasm of control cells treated with 
FasL for 4 h, but it was only weakly produced in Jurkat-Tat101 even after treatment for 
18 h (Fig. 4B). In Jurkat-Tat72, the levels of cytosolic p89 were halfway between those 
detected in Jurkat-Tat101 and control cells. Measurement of caspase-3/-7 activity showed 
that the activation of these caspases in response to FasL was delayed in Jurkat-Tat101 
regarding Jurkat-Tat72 and control cells (p  0.05) (Fig. 4C). Measurement of the 
activation of caspase-8 showed 1.6-fold reduction in Jurkat-Tat101 (p  0.001), whereas 
the difference between Jurkat-Tat72 and control cells was lower (Fig. 4D). The cleavage 
of caspase-8 by immunoblotting showed in JurkatTat101 a great delay in the cleavage of 
procaspase-8 (p55) after treatment with FasL for 18 h. This was not observed in Jurkat-
Tat72. 
Release of Cytochrome c and Activation of Caspase-9 Are Impaired in Jurkat-Tat101 
Cells Due to High Stability of the Mitochondrial Inner Membrane Electrochemical 
Potential— Analysis by flow cytometry showed that the release of cytochrome c to the 
cytoplasm from the mitochondrial intermembrane space in response to treatment with 
FasL for 4 or 18 h was reduced nearly 2-fold in Jurkat-Tat101 cells, whereas no 
significant difference with control cells was observed in Jurkat-Tat72 cells (Fig. 5A). 
These results were confirmed by confocal microscopy through the analysis of the 
subcellular localization of cytochrome c (Fig. 5B). Consistent with data obtained by flow 
cytometry, the mitochondria of Jurkat cells with stable expression of Tat101 were more 
resilient to release cytochrome c in response to FasL. Besides, the mitochondria of 
Jurkat-Tat101 cells showed a more diffuse and less compact distribution than those in 
Jurkat-Tat72 and control cells. 
Cytosolic protein extracts for Jurkat-Tat101, Jurkat-Tat72, and control cells treated with 
FasL for 4 or 18 h were analyzed by immunoblotting using an antibody against precursor 
p46 and active forms p37/p35 of caspase-9. As shown Fig. 6A, p37/ p35 were only 
detected in control cells and weakly in JurkatTat72 cells after treatment with FasL for 4 
h, but no band corresponding to the activation of caspase-9 was observed in Jurkat-
Tat101. After 18 h, p37/p35 were detected in the cytosol of Jurkat-Tat101, but there was 
3.5-fold more unprocessed procaspase-9 than in control cells, proving that the impaired 
release of cytochrome c in these cells resulted in a delayed activation of caspase-9. This 
deficient caspase-9 activation was confirmed by measuring the activity of caspase-9 by 
chemiluminescence, which was 1.7-fold lower in Jurkat-Tat101 cells (p  0.001) (Fig. 6B). 
The mitochondrial membrane potential gradient (m) was measured by using the cationic 
lipophilic dye JC-1 (68). The dispersion of green JC-1 monomers from the mitochondria 
throughout the entire cell, which correlates with the induction of apoptosis, was 
measured by flow cytometry after treatment with FasL for 4 or 18 h (Fig. 6C). The 
population of JurkatTat101 cells committed to apoptosis, low m and higher monomeric 
JC-1 with green fluorescence, was smaller than in Jurkat-Tat72 and control cells after 
treatment with FasL. This difference was mainly observed after 18 h of treatment, where 
nearly 30% of Jurkat-Tat101 cell population showed high resistance to lose the 
mitochondrial membrane potential, regarding control cells. In accordance, the population 
of living cells with higher m, where JC-1 formed aggregates with red fluorescence, was 
also 2.8-fold greater in Jurkat-Tat101. Jurkat-Tat72 cells showed an intermediate profile 
of mitochondrial membrane integrity loss with 1.8-fold higher m than control cells. As a 
result, the mitochondrial depolarization, measured by the decrease in the red/green 
fluorescence intensity ratio, was delayed by the intracellular expression of Tat101 and, 
with less intensity, by Tat72. 
Analysis by immunoblotting of BCL2 showed that the expression was enhanced in 
Jurkat-Tat101 in basal conditions, and its quantity was not significantly reduced even 
after treatment with FasL during 18 h (Fig. 6D). The expression of Bid (p22) diminishes 
as caspase-8 cleaves it to generate the truncated form tBid/p15 that translocates to the 
mitochondria and directly induces the outer membrane permeabilization (43). The 
expression of Bid/p22 was significantly reduced in JurkatTat72 and control cells after 
treatment with FasL, suggesting that tBid was being synthesized and translocated to the 
mitochondrial membrane. However, Bid/p22 remained uncleaved in Jurkat-Tat101, 
proving that the activation of caspase-8 was deficient in these cells. 
Tat Deregulates the Expression of Cellular Proteins Related to Apoptosis and to the 
Maintenance of Mitochondrial Outer Membrane Integrity—The whole proteome of 
Jurkat-Tat101, Jurkat-Tat72, and control cells was analyzed by LC-MS/MS in basal 
conditions. The analysis showed that Tat mostly induced the up-regulation of proteins 
related to the cell cycle and proliferation such as PHB, HEBP2/SOUL, NUDC, MCM2/3, 
PCNA, and NASP (Table 1). The expression of most of these proteins was more 
enhanced by the expression of Tat101 than Tat72. Besides, proteins related to apoptosis 
and stress response were also up-regulated by Tat, such as 14-3-3/, Bid, DJ-1/PARK7, 
and several heat shock proteins. More than 50% of the apoptotic proteins deregulated 
were related to the mitochondrial function, including ATP synthase and subunits, which 
were mainly enhanced by the expression of Tat101. Most of these proteins belong to 
interconnected cellular pathways, and in some cases their activation was related to 
caspase-3 activity. This was observed after analyzing the predicted protein interactions 
by STRING 9.0 database. As shown Fig. 7, caspase-3 was directly connected to Bid, 
HSPE1, HSPD1, YWHAZ, and PCNA. In turn, these proteins were connected with the 
other proteins whose expression was modulated by Tat, forming an intertwined network 
that included mostly all deregulated proteins. 
Intracellular Tat101 Deregulates Several NF-B-dependent Proteins Involved in the 
Control of Apoptosis—The expression of c-FLIPL/S was analyzed by immunoblotting 
(Fig. 8A). c-FLIPS, rather than c-FLIPL, which is the one that confers resistance to human 
T cells against Fas-mediated apoptosis (69), was 2.1- and 2.8-fold enhanced in Jurkat-
Tat72 and JurkatTat101 in basal conditions. Treatment with FasL for 18 h reduced the 
expression of c-FLIPL similarly in all cell types, but the expression of c-FLIPS was very 
different depending on the expression of Tat or the treatment with FasL. Jurkat-Tat101 
and Jurkat-Tat72 showed 10.5- and 3.8-fold more c-FLIPS expression than control cells, 
respectively, after treatment with FasL for 18 h. However, the expression of c-FLIPR/p43 
was enhanced 22.5- and 12.5-fold more in Jurkat-Tat101 and Jurkat-Tat72, respectively, 
than in control cells, in basal conditions. After treatment with FasL, the cleavage of c-
FLIPL to c-FLIPR/p43 was increased 30-fold more in both Jurkat-Tat101 and Jurkat-
Tat72 (see supplemental Fig. 2). 
As the expression of BCL2 and c-FLIP depends on NF-B activity, the ability of the main 
NF-B subunit p65/RelA to bind DNA was analyzed by DNA affinity immunoblotting 
assay in Jurkat-Tat101 and Jurkat-Tat72 cells in basal conditions, regarding control cells. 
As described previously, NF-B binding capacity was higher in Jurkat-Tat101 than in 
Jurkat-Tat72 and, increased in Jurkat-Tat101 (p  0.01) and 1.5-fold in Jurkatin turn, 
higher in Jurkat-Tat72 than in control cells (Fig. 8B) (23, Tat72 cells, regarding control 
cells (Fig. 8C). Treatment with 70). This was reflected in the enhancement of the 
expression of FasL did not reduce significantly the expression of CD69 on the T cell 
activation markers such as CD69, which was 3.3-fold cell surface (p  0.05). NF-B 
transcriptional activity was also measured by transfecting p3B-LUC vector (Fig. 8D). 
JurkatTat101 cells showed 20-fold more NF-B activity than control cells (p 0.01) and 4-
fold more than Jurkat-Tat72 (p 0.01), in basal conditions. The treatment with FasL for 4 
h reduced the NF-B activity in all cell types, but the differences with control cells were 
maintained (p  0.01). 
To identify other regulators of apoptosis related to NF-B, the expression of which could 
be modified by Tat, whole protein extracts from nonstimulated cells were hybridized in 
an antibody-based array that simultaneously detected 35 human apoptosis-related 
proteins, most of them related directly or indirectly to NF-B activity. The expression of 
11 proteins was deregulated in Jurkat-Tat101 and Jurkat-Tat72, regarding the expression 
levels detected in control cells (Table 2). Both C-IAP2 and XIAP were enhanced in 
Jurkat-Tat101, whereas only XIAP was enhanced in Jurkat-Tat72 cells. Heat shock pro- 
teins 70 kDa (HSPA1A/1B) and 60 kDa (HSPD1) were also upregulated in both Jurkat-
Tat101 and Jurkat-Tat72 cells. Surprisingly, Jurkat-Tat101 also showed great quantities 
of proapoptotic factors such as lymphotoxinor Bax, which were not detected in Jurkat-
Tat72. On the contrary, the expression of BCL2 interacting mediator of cell death 
(BIM/BCL2L11) was diminished 2-fold in Jurkat-Tat101. The analysis of the predicted 
interactions between these proteins by STRING 9.0 database showed a connection 
between all of them and that p65/RelA had a central position in the center of this 
complex network (Fig. 8E). 
Tat-mediated Activation of NF-B through the ESKKKVE Motif Is Greatly Involved in the 
Induction of Resistance to Fasmediated Apoptosis—The motif 86ESKKKVE92 located in 
Tat second exon has been described as critical for Tat-mediated NF-B transactivation 
(70). Mutagenesis was performed in this motif to render a protein that should not be able 
to induce NF-B activity. Both pTRE2hyg-Tat101 ESKKKVE (wild type) and 
pTRE2hyg-Tat101 ESRVNVV (mutated) were transiently co-transfected in Jurkat-Tet-
Off cells along with p3B-LUC vector. As shown Fig. 8F, Tat ESRVNVV induced a 1.9-
fold lower activation of NF-B activity than Tat ESKKKVE (p  0.001). The treatment of 
these transfected cells with FasL for 4 h showed that Tat ESKKKVE was more efficient 




Activation of death signals is part of the antiviral immune response in the infected cell 
and represents a major threat to virus (71, 72). Many viruses have evolved mechanisms 
to inhibit apoptosis to the extent of the survival of infected cells, enhance the production 
of viral progeny, and permit the establishment of viral persistence. DNA viruses, such as 
adenovirus, EpsteinBarr, or African swine fever virus, encode viral anti-apoptotic 
proteins similar to cellular proteins, such as D-type cyclin, BCL2, and c-FLIP (73), 
whereas the herpes simplex virus type 1 (HSV-1) maintains the cellular BCL2 levels 
through different mechanisms, including the activation of p38 MAPK (74). It is not well 
known whether the RNA viruses have similar mechanisms, but HIV-1-infected cells 
appear to have developed certain resistance to apoptosis to prolong the viral production 
(13, 14). The molecular mechanisms underlying this protection are not fully 
comprehended, but the intracellular expression of viral regulatory proteins such as Vpr or 
Tat during the first step of the viral replication may be involved. Interestingly, both 
proteins seem to overlap their function, suggesting that preventing apoptosis during the 
first steps of the HIV-1 replication is a crucial step for the viral cycle and its 
pathogenesis. Vpr exerts a dual role on regulating apoptosis during HIV-1 infection 
because, although extracellular or high intracellular levels of Vpr induce cellular death 
through the alteration of mitochondrial membrane permeabilization (75, 76), an 
intracellular low concentration of Vpr seems to protect against FasL-mediated apoptosis 
in Jurkat cells (9). Similarly, we and others have previously described that the 
intracellular expression of HIV-1 Tat regulator protein appears to have an anti-apoptotic 
effect (23, 28, 77), but the mechanisms underlying this function of Tat have not been 
described yet. In this work, we show that the expression of the Tat second exon within 
the full-length Tat protein (Tat101) during HIV-1 replication enhances cellular survival 
in T lymphocytes during the first 72 h post-infection, and we describe the mechanisms 
involved. Furthermore, we demonstrated that PBLs, specifically, CD4 T cells, and Jurkat 
cells expressing intracellular full-length Tat (Tat101) were more resistant to Fas-induced 
apoptosis than those expressing only the first exon (Tat72) or Tat-free control cells, and 
the molecular mechanisms involved in this process are described. Our data suggest that 
the protection against apoptosis mediated by full-length Tat occurred through two major 
mechanism as follows: first, a higher maintenance of the mitochondrial membrane 
potential and subsequent impairment in caspase-3 activation; and second, activation of 
NF-B, which in turn induces the expression of survival proteins such as c-FLIP and 
BCL2. In these mechanisms, the presence of the second exon within full-length Tat 
appeared to be of paramount importance. 
Resistance to apoptosis in HIV-1 persistently infected T cells is related to the 
mitochondrial apoptotic pathway (78, 79). In Jurkat cells, the induction of Fas-mediated 
apoptosis requires an amplification step through the mitochondrial cell death pathway to 
activate caspase-3 (39, 45). This is achieved through the translocation of tBid to the 
mitochondrial membrane and subsequent release of cytochrome c (45, 47). The 
intracellular expression of Tat101 was able to maintain the mitochondrial outer 
membrane integrity by different mechanisms, delaying the release of cytochrome c and 
causing an inefficient activation of caspase-9 and -3. Tat72 was less competent than 
Tat101 to exert this protection. The quantification of caspase-3 activity by 
chemiluminescence did not correlate well with the cleavage of procaspase-3 to p17/p11 
active forms in Jurkat-Tat72 cells. However, the lesser inhibitory effect of Tat72 on the 
activation of caspase-3 was confirmed through the analysis of PARP-1 cleavage, which 
was undoubtedly less effective in Jurkat-Tat101 than in Jurkat-Tat72. 
The measure of m showed that the mitochondrial depolarization was lower in Jurkat-
Tat101 in response to FasL, likely due to the control exerted by c-FLIPS over the activity 
of caspase-8 and a lower cleavage of Bid but also due to the overexpression of other 
proteins such as BCL2 that may counteract this mechanism and stabilize the 
mitochondrial membrane (80, 81). BCL2 was described to be overexpressed by full-
length Tat (55, 56), inducing protection against mitochondrially mediated apoptosis in 
Jurkat (82). BCL2 expression did not decrease in Jurkat-Tat101 even after a long 
treatment with FasL. As the cleavage of Bid and BCL2 levels was quite similar in 
JurkatTat72 than in control cells, this would explain the higher mitochondrial 
depolarization observed in these cells, reinforcing the assumption that the ability of Tat 
to protect against apoptosis mostly resided in the second exon. 
However, BCL2 was not the only protein responsible for delaying apoptosis as other 
proteins overexpressed by Tat101 and Tat72 were also able to stabilize the mitochondrial 
membrane potential such as several mitochondrial heat shock proteins (HSPD1, HSPE1, 
and HSPA1), nucleophosmin (NPM1), and BCL2-associated transcription factor 1 
(BCLAF1). Overexpression of HSPs has been related to an increase in BCL2, 
mitochondrial membrane potential stabilization, impairment of cytochrome c release, 
caspase-3 inhibition, and suppression of PARP cleavage (83–85). HSPE1 was acetylated 
at Lys-99 in Jurkat-Tat101, which has been related to a higher gene expression regulation 
(86). BCLAF1 was also overexpressed by Tat101 and Tat72 and was heavily 
phosphorylated at Ser-177 and Ser-512 mainly in Jurkat-Tat101. Recent studies proved 
that BCLAF1 has a major role in T cell activation (87, 88). Besides, nucleolar NPM1 
suppresses apoptosis by inhibiting caspase-mediated activation of DNase, favoring 
genomic stability and DNA repair (89), as well as by blocking p53 mitochondrial 
localization (90). NPM1 is known to interact with HIV-1 Rev (91) and Tat, being critical 
for Tat nuclear localization and Tat-mediated transcription (92). Although NPM1 was 
overexpressed in both Jurkat-Tat101 and Jurkat-Tat72, it was deamidated at Asn-210 in 
Jurkat-Tat72; therefore, it was not fully functional in these cells. NPM1 also enhances the 
expression of the pro-apoptotic protein Bax and acts as a chaperone, binding only to 
activated and conformationally altered Bax (93). Bax was actually overexpressed in 
Jurkat-Tat101, as well as the BH3-domain only SOUL. SOUL has a similar function to 
Bax, inducing the mitochondrial membrane permeabilization and subsequent release of 
cytochrome c. The high expression of Bax in Jurkat-Tat101 could indicate a higher 
sensitivity to apoptosis. However, the pro-apoptotic function of Bax should be activated 
through the interaction with other factors as Bid or Bim, promoting a critical 
conformational change in Bax necessary for its death capacity (94, 95). In Jurkat-Tat101 
cells, Bid was not efficiently cleaved to tBid, and the expression of Bim was reduced 
nearly 3-fold, indicating that the pro-apoptotic function of Bax was likely impaired by 
deficient activation. Moreover, Bim can be inhibited through its interaction with 
YWHAZ, a member of the 14-3-3 protein family that antagonizes the activity of 
proapoptotic proteins such as Bad, Bim, and Bax (96, 97). YWHAZ was enhanced in 
both Jurkat-Tat101 and Jurkat-Tat72, although it was heavily deamidated in Jurkat-
Tat72, likely rendering a not fully functional protein, unable to control the proapoptotic 
proteins. Other anti-apoptotic factors such as PHB contributed to the higher protection 
against apoptosis provided by Tat101 but not Tat72. PHB is a potent survival factor that 
inhibits the release of cytochrome c and caspase-3 activation (98, 99), and it was 
increased 70-fold in Jurkat-Tat101, which was 2-fold higher than in Jurkat-Tat72. 
Overall, these results indicated that the higher stability of the mitochondrial membrane 
integrity in Jurkat-Tat101 was due to a group of stabilizing proteins acting together to 
prevent the release of cytochrome c. A direct consequence of this inhibition was the 
inefficient activation of caspase-3, which could hinder the activation of other cellular 
pathways as the cell cycle control. In fact, DNA replication factors as MCM2 and MCM3 
were overexpressed in Jurkat-Tat101. MCM3 is the substrate for caspase-3 cleavage, and 
the truncated forms contribute to initiate apoptosis (100), inactivating the MCM complex 
and preventing DNA replication (101). The low caspase-3 activity detected in Jurkat-
Tat101 would contribute to MCM3 stability and therefore to the maintenance of the 
MCM complex, avoiding apoptosis. Other factors related to cell cycle progression, 
cytokinesis, and cell proliferation were also overexpressed in Jurkat-Tat101, such as 
NUDC, NASP, and PCNA (102–105). The overexpression of somatic NASP has been 
related to changes in NF-B activity (106), which is known to be enhanced by Tat (23, 
70). NF-B may in turn activate the expression of several potent anti-apoptotic factors as 
those belonging to IAP family. The expression of XIAP was enhanced in both 
JurkatTat101 and Jurkat-Tat72, but C-IAP2 was only overexpressed in Jurkat-Tat101, 
nearly 40 times. XIAP is a potent inhibitor of initiator caspases, caspase-9 (107), as well 
as execution caspases, caspases-3 and -7 (108), preventing both CD95- and Bax-induced 
apoptosis (109, 110). This would explain the high quantities of procaspase-3, -8, and -9 
that were detected in Jurkat-Tat101 even after treatment with FasL. C-IAP2 is a 
component of the tumor necrosis factor receptor 2 (TNFR2) complex that inhibits cell 
death by direct repression of caspase activity (111), and it also targets for ubiquitin 
degradation several pro-apoptotic components of the TNF-signaling pathway (112). 
Moreover, there should be a deregulation in the TNF signaling pathway because the 
expression of several components such as TNFRSF1A, Fas receptor, and TNF-
/lymphotoxin showed an anomalous expression. Likely, the higher release of TNF 
cytokines by Jurkat-Tat cells was able to activate NF-B via autocrine feedback, keeping a 
sustained activation of this transcription factor (113). As Tat72 lacks the motif 86 92 
ESKKKVE , located in the second exon, which has been described as critical for NF-B 
transactivation (70), the lower NF-B basal activity detected in Jurkat-Tat72 regarding 
JurkatTat101 should be related to this motif. Accordingly, Tat101 with mutated 
86ESRVNVV92 motif was less efficient than wild-type Tat101 to activate NF-B and 
protect Jurkat against FasL-mediated apoptosis. 
In summary, intracellular HIV-1 Tat deregulated the expression of several proteins 
related to apoptosis, rendering an antiapoptotic general effect able to protect PBLs and 
Jurkat from FasL-induced apoptosis. This was achieved through the high stability of the 
mitochondrial membrane integrity because Tat101 increased the expression of several 
proteins, HSPs, NPM1, and PHB, committed to avoid mitochondrial depolarization, 
stabilize the cell cycle, and counteract pro-apoptotic factors such as Bid, Bim, or Bax. 
This effect was also achieved through the ability of Tat101 to activate NF-B, an essential 
transactivating factor that promotes cell survival through different mechanisms, such as 
the up-regulation of C-IAP2, XIAP, BCL2, and c-FLIPS. As Tat72 lacks the essential 
motif ESKKKVE for activating NF-B, this could be the most important mechanism 
through which Tat101 exerts its protective function. A scheme of the most important 
factors interfering with the apoptotic pathway in T lymphocytes, for which expression 
was modified by Tat, is depicted in Fig. 9. 
In conclusion, Tat101-mediated protection against apoptosis would allow a prolonged 
HIV-1 production and spread and might explain why apoptosis mostly occurs in 
bystander uninfected cells. This viral strategy would be mainly achieved through the 
second exon. A better understanding of the molecular mechanisms responsible for the 
resistance to apoptosis in HIV-infected T cells is essential to fully characterize the ability 
of HIV-1 to establish a long term infection. 
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TABLES AND FIGURES 
 
 
FIGURE 1. FasL-mediated apoptosis was reduced in PBLs expressing intracellular 
Tat101. A, resting PBLs were transiently transfected with pCMV-Tat72 or pCMV-
Tat101 expression vectors or with pcDNA3 as negative control. pEYFP-C1 was used as 
control of transfection efficiency. PBLs were maintained for 3 days without stimulus, and 
then were treated with FasL for 18 h. Viability was measured by chemiluminescence. The 
bar diagram represents the media of three independent experiments, and lines on top of 
 
 
the bars correspond to the mean   S.E. Two-way ANOVA with Bonferroni postest 
analysis was performed for statistical analysis; ** indicates p  0.01. B, Tat expression and 
nuclear localization were confirmed by immunofluorescence. DAPI was used for nuclear 
staining. C, resting PBLs were transiently transfected with pCMV-Tat72 or pCMV-
Tat101 expression vectors or with pcDNA3 as negative control. pEYFP-C1 was used as 
control of transfection efficiency. PBLs were maintained for 3 days without stimulus and 
then were treated with FasL for 18 h. Cells were stained with a monoclonal antibody 
against CD4 conjugated with PE and then with PI. Signals corresponding to EYFP, PE, 
and PI were analyzed by flow cytometry in FL1, FL2, and FL3 channels, respectively. 
SSC/FSC dot plot was used to select living (PI ) cells (region R1) as follows: red events 
correspond to PI , living cells; magenta events correspond to PI, dead cells; black 
events correspond to cellular debris. The numbers in the PI /EYFP/CD4 dot plots 
show the percentage of CD4/EYFP cells within the PI region (region R3). The bar 
diagram represents the media of three independent experiments, and the lines on top of 






FIGURE 2. Tat101reduced FasL-mediated apoptosis in HIV-1-transfected PBLs. A, 
PBLs were transfected with pNL4.3-TatM1I and pCMV-pTat72 or pCMV-Tat101 
expression vectors. pcDNA3 was used as a negative control. pEYFP-C1 was used as a 
control of transfection efficiency. HIV-1 replication was allowed for 3 days before 
treatment with FasL for 18 h. Viability was measured by chemiluminescence. The bar 
diagram represents the media of three independent experiments, and lines on top of the 
bars correspond to S.E. Two-way ANOVA with Bonferroni pos-test analysis was 
 
 
performed for statistical analysis (* and ** indicates p  0.05 and p  0.01, respectively). B, 
expression of HIV-1 genes was monitored by quantifying the expression of the env/nef 
genes by quantitative RT-PCR using -ACTIN as internal control. C, resting PBLs were 
transiently transfected with pNL4.3-TatM1I and pCMVpTat72 or pCMV-Tat101 
expression vectors. pcDNA3 was used as negative control. pEYFP-C1 was used as 
control of transfection efficiency. PBLs were maintained for 3 days without stimulus and 
then were treated with FasL for 18 h. Cells were stained with a monoclonal antibody 
against CD4 conjugated with PE and then with PI. Signals corresponding to EYFP, PE, 
and PI were analyzed by flow cytometry in FL1, FL2, and FL3 channels, respectively. 
SSC/ FSC dot plot was used to select living (PI ) cells (region R1) as follows: red events 
correspond to PI , living cells; magenta events correspond to PI, dead cells; black 
events correspond to cellular debris. The numbers in the PI /EYFP/CD4 dot plots 
show the percentage of CD4/EYFP cells within the PI region (region R3). The bar 
diagram represents the media of three independent experiments, and the lines on top of 





FIGURE 3. Tat101 reduced FasL-mediated apoptosis inHIV-1-transfected Jurkat cells 
and in Jurkat cells with stable expression of intracellular Tat101. A, Jurkat E6-1 cells 
were transfected with pNL4.3-TatM1I together with pCMV-Tat72 or pCMV-Tat101 
expression vectors. pcDNA3 was used as negative control. pEYFP-C1 was used as control of 
transfection efficiency. After 3 days in culture, cells were treated with FasL for 4 h. Viability 
was measured by chemiluminescence. The bar diagram represents the media of three 
independent experiments, and lines on top of the bars correspond to S.E. Two-way ANOVA 
with Bonferroni pos-test analysis was performed for statistical analysis (* indicates p  0.05). 
HIV-1 replication was monitored by quantifying the expression of the env/nef genes by 
 
 
quantitative RT-PCR using -ACTIN as internal control. B, Jurkat-Tat101, Jurkat-Tat72, and 
control cells were treated with FasL for 2, 4, 6, and 18 h and then stained with annexin-V-
FITC to measure by flow cytometry the percentage of apoptotic cells. C, Jurkat-Tat101, 
Jurkat-Tat72, and control cells were treated with FasL during 4 h and then stained with PI. 
The induction of apoptosis was measured by flow cytometry. Region R1 was used to select 
the living PI cells in the groups of untreated cells, displayed as SSC/FSC dot plots. The 
percentage of apoptotic cells (PI) was determined within R1 in treated cells and then 
represented as histograms where the basal cell death (continuous line) was compared with the 
apoptosis induced after treatment with FasL (discontinuous line). The numbers shown 
correspond to the percentage of apoptotic cells within R1 after subtracting the basal death. D, 
Jurkat-Tat101, Jurkat-Tat72, and control cells were stained with a monoclonal antibody 
against Fas receptor (FasR/CD95) and a secondary antibody conjugated with FITC. The 
percentage of cells expressing Fas was measured by flow cytometry. The histograms 
compare the isotype control (discontinuous line) with the expression of FasR (continuous 
line) on the cell surface. Numbers shown are the percentage of cells expressing CD95 after 







FIGURE 4. Activation of caspase-3 and -8 was impaired in Jurkat-Tat101 treated with FasL. A, 
procaspase-3 cleavage was analyzed by immunoblotting using an antibody against procaspase-3 (p32) 
and active fragments p17/p11 in protein extracts obtained from Jurkat-Tat101, Jurkat-Tat72, and 
control cells treated or not with FasL for 4 or 18 h. -Actin was used as internal loading control. Gel 
bands were quantified by densitometry, and the background noise was subtracted from the images. The 
relative ratio of the optical density units corresponding to each sample was calculated regarding the 
internal control (-actin) per each lane. B, cleavage of PARP-1 was analyzed by using a monoclonal 
antibody against the cleaved fragment p89. -Actin was used as loading control. C, caspase-3/-7 
 
 
and p  0.001, respectively. 
  
activation was measured by chemiluminescence in cells treated or not with FasL. D, caspase-8 
activation was measured by chemiluminescence in cells treated or not with FasL. Levels of procaspase-
8 were analyzed by immunoblotting using an antibody against procaspase-8 (p55) in protein extracts 
obtained from Jurkat-Tat101, Jurkat-Tat72, and control cells treated with FasL for 18 h. -Actin was 
used as internal loading control. The bar diagrams show the media of relative RLUs fold from three 
independent experiments, and the lines on the top of the bars represent the S.D. Two-way ANOVA 





FIGURE5. Release of cytochrome c induced by FasLwas reduced in Jurkat-Tat101. 
A,release of cytochrome c from the mitochondria was quantified by flow cytometry in 
Jurkat-Tat101, Jurkat-Tat72, and control cells treated or not with FasL during 4 or 18 h. 
The histograms correspond to one representative experiment out of three and compare the 
percentage of cytochrome c that was retained in the mitochondrial intermembrane space 
(continuous line; marker M1) versus the cytochrome c released after treatment with FasL 
(discontinuous line; marker M2). B, release of cytochrome c (Cyt. c) was analyzed by 
immunofluorescence. After staining with the Mitotracker probe, the cells were fixed and 
 
 
stained with a monoclonal antibody against cytochrome c and a secondary antibody 









potential. A, cleavage of procaspase-9 was analyzed by immunoblotting in cytosolic protein 
extracts obtained from Jurkat-Tat101, Jurkat-Tat72, and control cells treated or not with FasL 
during 4 or 18 h, using an antibody against the procaspase-9 (p46) and active caspase-9 
(p37/p35) fragments.-Actin was used as loading control. Gel bands were quantified by 
densitometry, and the background noise was subtracted from the images. The relative ratio of 
the optical density units corresponding to each sample was calculated regarding the internal 
control (-actin) per each lane. B, caspase-9 activity was measured by chemiluminescence. 
The bar diagram shows the media of relative RLUs fold from three independent experiments, 
and the lines on the top of the bars represent the S.D. Two-way ANOVA with Bonferroni 
post-test analysis was performed for statistical analysis, and *, **, and *** correspond to p  
0.05, p  0.01, or p  0.001, respectively. C, mitochondrial membrane potential gradient (m) was 
measured by flow cytometry using the lipophilic dye JC-1. Red fluorescent aggregates in the 
undamaged mitochondria were represented in a dot plot versus the green fluorescent 
monomers dispersed through the cytosol. The numbers upper left in the diagrams represent 
the cells with stable mitochondrial membrane integrity; the numbers lower right represent the 
loss of mitochondrial membrane integrity. A representative experiment out of three is shown. 
D, expression of BCL2 and Bid (p22) was analyzed by immunoblotting, and-actin was used 





FIGURE 7. Network of predicted interactions between proteins related to apoptosis 
and mitochondrial membrane integrity, as specified in Table 1, the expression of 
which was modified in Jurkat-Tat101 and Jurkat-Tat72 versus control cells. 
Medium confidence score level was 0.400. Caspase-3 was included to evaluate its central 
point in the network. Data supporting protein-protein interactions were derived from 
experimental studies (dark purple lines), homology (light purple lines), databases (light 
blue lines), text mining (light green lines), concurrence (dark blue lines), and co-








FIGURE 8. NF-B-dependent proteins involved in the control of apoptosis were up-
regulated in Jurkat-Tat101. A, expression of c-FLIPL (55 kDa), c-FLIPR (43 kDa), and c-
FLIPS (28 kDa) isoforms was analyzed by immunoblotting in cytosolic protein extracts from 
Jurkat-Tat101, Jurkat-Tat72, and control cells treated or not with FasL for 4 or 18 h. -Actin 
was used as loading control. B, NF-B activity was analyzed in basal conditions by using 
DNA affinity immunoblotting assay. Gel bands were quantified by densitometry, and the 
background noise was subtracted from the images. The relative ratio of the optical density 
units corresponding to each sample was calculated regarding the internal control (-actin) per 
each lane. C, Jurkat-Tat72, Jurkat-Tat101, and control cells were treated with FasL during 4 
h and then stained with an antibody against CD69 conjugated with PE. The percentage of 
cells expressing CD69 on the cell surface was measured by flow cytometry. The bar diagram 
represents the percentage of cells expressing CD69 after subtracting the isotope control. D, 
NF-B-dependent transactivation activity was measured by transient transfection of vector 
p3B-LUC. Fold mean of RLUs corresponding to three independent experiments is 
represented, and lines on the top of the bars correspond to S.D. E, network of proteins related 
to apoptosis and identified by antibody-based microarray (see Table 2), expression of which 
was modified in Jurkat-Tat101 and Jurkat-Tat72 versus control cells. Predicted protein-
protein interaction was obtained using a medium confidence score level (0.400). Data 
supporting protein-protein interactions derived from experimental studies (reddish purple 
lines), homology (light purple lines), databases (light blue lines), text mining (light green 
lines), and co-expression (black lines). The color of the nodes is arbitrary. F, Jurkat Tet-Off 
cells were transiently co-transfected with p3B-LUC vector and pTRE2hyg-Tat101 
ESKKKVE (wild type), pTRE2hyg-Tat101 ESRVNVV (mutated), or pTRE2hyg empty 
vector as negative control. After 18 h, NF-B activity was measured by chemiluminescence. 
Fold of relative RLUs regarding the control cells are represented (upper bar diagram). Cells 
were then treated with FasL for 4 h, and apoptosis was measured by PI staining and analyzed 
by flow cytometry (lower bar diagram). The bar diagrams show the media obtained from 
three independent experiments, and lines on the top of the bars represent the S.D. Two-way 
ANOVA with Bonferroni post-test analysis was performed for statistical analysis. Symbols 





FIGURE 9. Model summarizing the steps in Fas apoptotic pathway that were 




TABLE1. Selected proteins differently expresse and detected by mass spectrometry 
in protein extracts from Jurkat-Tat101 and Jurkat-Tat72 cells, in comparison with 
Tet-Off cells  
 
Amino acidic residues with post-translational modifications (PTMs) are underlined and in 
lowercase. PTMs detected were as follows; p, phosphorylation; a, acetylation; d, 




TABLE2. Proteins differentially expressed and detected by human apoptosis 
antibody array in protein extracts from Jurkat-Tat72 and Jurkat-Tat101 in 




Supplemental figure legends 
Fig. 1. Obtaining the HIV-1 Tat-defective clone NL4.3TatM1I. A. The start codon of the 
tat gene (methionine, M) in the infectious clone pNL4.3-wt was changed into isoleucine 
(I) by introducing a missense point mutation through site-directed mutagenesis (TatM1I). 
This strategy did not affect the splicing regulator elements located near the start codon of 
the tat gene in HIV-1 genome (ESE2: exonic splicing enhancer 2; ESS2: exonic splicing 
silencer 2). B. HEK293T cells were transfected with pNL4.3-wt or pNL4.3-TatM1I 
vectors and then MT-2 cells were infected with the resultant culture supernatant for 5 
days. HIV-1 replication was assessed by quantifying the concentration of p24 (ng/ml) in 
MT-2 culture supernatant. C. Syncytia formation was observed in MT-2 cells infected 
with NL4.3-wt or NL4.3-TatM1I for 5 days by light microscopy. Syncytia are indicated 
with white arrows. D. Jurkat cells were co-transfected with pNL4.3-wt or pNL4.3-
TatM1I vectors, together with pCMV-Tat101 expression vector. pEYFP-C1 vector was 
used as a control of transfection efficiency. The expression of Tat and its nuclear 
localization was analyzed by immunofluorescence 48h after transfection using a 
monoclonal antibody directed against Tat and a secondary antibody conjugated with 
Alexa-546. Nuclei were stained with Dapi. E. Jurkat-Tat72 and Jurkat-Tat101 cells were 
transfected with pNL4.3-TatM1I, using Jurkat TetOff as negative control. Efficient 
transcription of HIV-1 genome from Tat-defective NL4.3-TatM1I genome was 
determined by qRT-PCR using specific primers against the env/nef gene. β-actin was 
used as housekeeping gene. Data shown correspond to the relative HIV-1 gene 
expression regarding control cells (left bar diagram). The concentration of p24 (ng/ml) 
was assessed in culture supernatants by ELISA (right bar diagram). The virions produced 
by Jurkat-Tat72 and Jurkat-Tat101 were infectious, as was assessed by the subsequent 
infection of MT-2 cells (data not shown). 
Fig. 2. Pattern of expression of c-FLIP in Jurkat-Tat72 and Jurkat-Tat101 cells. Changes 
in the pattern of expression of c-FLIP were analyzed by immunoblotting in Jurkat-Tat72 
or Jurkat-Tat101, treated or not with FasL for 4 or 18 hours. Different exposures allowed 
the detection of all forms of c-FLIP (c-FLIPS (p28), c-FLIPR (p43) and c-FLIPL (p55)). 
Non saturated bands were used for quantifying the expression of the different forms by 
 
 
densitometry using the signal detected in untreated control cells as the basal reference. * 
indicates a non-specific band. 
Supplementalmaterial and methods 
HIV-1 infection- Infectious supernatants were obtained from calcium phosphate 
transfection of HEK293T cells with plasmids pNL4.3-wt or pNL4.3-TatM1I. Culture 
supernatans were used to infect MT-2 cells for 2 hours at gently rotation, room 
temperature. Cells were then centrifuged at 600xg for 30min at 25°C. After extensive 
washing with PBS1x, cells were left in culture for 5 days. Supernatants were collected 
and p24 antigen was measured by using an enzyme-like immunoassay (InnotestTM HIV 
Ag mAb; Innogenetics, Barcelona, Spain). 
Cells- HEK293T cells were grown in DMEM (Dulbecco’s modified Eagle Medium, 
Gibco) with 10% fetal bovine serum (Gibco) supplemented with penicillin/streptomycin 
(100U and 0.1 mg/ml, respectively) and 4mM L-glutamine (Gibco).  
 
 




Figure 2 Supplemental data 
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